New drug targets Hard-to-Treat cancers with PIK3CA mutation

NCT ID NCT05216432

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants will receive RLY-2608 alone or combined with other cancer drugs to find the safest dose and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RLY-2608 (a targeted drug that blocks a specific mutant protein in cancer cells)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific genetic mutation (PIK3CA), potentially slowing cancer growth.

What could go wrong

This is an early Phase 1 trial, so the drug may not work as hoped or could cause serious side effects. It is also only for people with a specific mutation, so it won't apply to most cancer patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boca Raton Clinical Research (BRCR) Global

    WITHDRAWN

    Plantation, Florida, 33322, United States

  • Centre Léon Bérard

    RECRUITING

    Lyon, Auvergne-Rhône-Alpes, 69008, France

  • Columbia University Herbert Irving Comprehensive Cancer Center

    RECRUITING

    New York, New York, 10032, United States

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Florida Cancer Specialists

    RECRUITING

    Orlando, Florida, 32827, United States

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • HealthONE

    RECRUITING

    Denver, Colorado, 80218, United States

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Inova Schar Cancer Center

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Institut Catala D'Oncologia - Badalona (ICO Badalona)

    RECRUITING

    Barcelona, 08916, Spain

  • Institute Bergonié

    RECRUITING

    Bordeaux, 33076, France

  • Instituto Valenciano de Oncologia

    RECRUITING

    Valencia, Valencia, 46009, Spain

  • Istituto Europeo di Oncologia IRCCS

    RECRUITING

    Milan, 20141, Italy

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering

    RECRUITING

    New York, New York, 10065, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22301, United States

  • NYU Langone

    RECRUITING

    New York, New York, 10016, United States

  • Peter MacCallum Cancer Center

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Renown Regional Medical Center

    RECRUITING

    Reno, Nevada, 89502, United States

  • Rutgers University

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • START Barcelona

    RECRUITING

    Barcelona, Catalonia, 08023, Spain

  • START Madrid - Hospital Fundacion Jimenez Diaz

    RECRUITING

    Madrid, 28040, Spain

  • St Vincents Hospital

    RECRUITING

    Sydney, New South Wales, 2019, Australia

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • The University of Arizona Cancer Center

    RECRUITING

    Tucson, Arizona, 85724, United States

  • The University of Texas M.D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • UW Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • University of California-San Diego

    RECRUITING

    San Diego, California, 90293, United States

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75235, United States

  • University of Utah- Huntsman Cancer Center

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Vall d'Hebron Instituto de Oncologia

    RECRUITING

    Barcelona, Barcelona, 08035, Spain

  • Washington University School of Medicine St. Louis

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States